Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight

Group 1 - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is considered a fundamentally strong penny stock, with Acadian Asset Management LLC increasing its holdings by 25.9% in Q1, acquiring 451,044 shares to reach a total of 2,195,191 shares, representing a 2.03% ownership stake [1][2] - The company is showing potential for future success despite a history of failures, as it announced that new data from its Phase 2a trial of ATI-2138 for atopic dermatitis will be presented at the 2025 EADV Congress in Paris [2][3] - ATI-2138 is a selective oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to severe atopic dermatitis, with effectiveness discussed in a session led by Dr. Jessica Beaziz-Tordjman [3][4] Group 2 - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Pennsylvania, focused on developing novel drug candidates for immune-inflammatory diseases, operating through Therapeutics and Contract Research segments [4]